ARTES Biotechnology


ARTES Biotechnology is a global and reliable technology provider for the production of recombinant proteins, specializing in microbial cell line and process development for vaccines, biopharmaceuticals, biosimilars, and enzymes. They offer transfer processes for enzymes, vaccines, and biosimilars, and have a broad portfolio of proprietary technologies including VLP vaccine development. The company operates worldwide from its facilities in Langenfeld, Germany, and has a history of over 20 years of successful partnerships with human and animal health companies, enzyme manufacturers, and the cosmetic, diagnostic, and nutrition industries.

Industries

biotechnology
genetics
pharmaceutical

Nr. of Employees

small (1-50)

ARTES Biotechnology


Products

Research reagents: recombinant antigens, enzymes and functional proteins

Catalog of recombinant research reagents produced in microbial expression systems for use in academic and industrial laboratories.

Recombinant Human Serum Albumin (rHSA) — research grade

Small‑batch recombinant human serum albumin produced in yeast for laboratories and industry needing high‑quality recombinant albumin for research applications.


Services

CDMO services: microbial cell line and process development

Contract development services for microbial production cell lines and process development for recombinant proteins and vaccines, including feasibility studies, expression optimization, cell bank generation, and preliminary fermentation.

CDMO services: fermentation and downstream process development

Upstream and downstream process development focusing on reproducibility, cost reduction and transferability to cGMP manufacturing; includes in‑process controls and assay development.

Manufacturing of non‑GMP and cGMP material

Manufacturing services for test and preclinical material at non‑GMP and cGMP standards, including upscaling, quality control, method transfer and project management.

VLP vaccine development and antigen presentation services

Design and development of VLP‑based vaccine candidates and antigen display strategies, including expression in yeast hosts, VLP purification process development and immunogenicity testing in animal models.

Technology transfer and licensing services

Out‑licensing and transfer of processes, cell lines and documentation with training and on‑site support; negotiation of commercial licensing terms and technical implementation support.

Expertise Areas

  • Microbial cell line development
  • Fermentation and downstream bioprocess development
  • Virus‑like particle (VLP) vaccine development
  • Technology transfer and licensing of bioprocesses
  • Show More (6)

Key Technologies

  • Hansenula polymorpha yeast expression
  • Pichia and Saccharomyces yeast expression
  • E. coli expression systems
  • Virus‑like particle (VLP) platforms for antigen display
  • Show More (6)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.